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The detection of minimal residual disease (MRD) in 
patients with acute leukemia has been studied for about 
15 years by different groups in both the United States and 
Europe. It has been found that MRD detection can be 
performed using molecular and immunophenotypic aber-
rancies that are present in the leukemic clone at diagnosis 
and not in normal bone marrow. When performing MRD 
assessments after chemotherapy, it is possible to identify 
patients at risk for relapse. This review is not an overview 
of all MRD studies, but rather discusses the possibilities 
for optimizing MRD detection, the use of ﬂow cytometry 
versus polymerase chain reaction techniques, and the 
implications for future patient treatment. When informa-
tive, we compare literature on MRD in acute myeloid 
leukemia (AML) with information from MRD studies in 
acute lymphoblastic leukemia. Finally, we address the 
promising detection of AML stem cells, the likely cells 
of origin in AML, for prediction of clinical outcome and 
guidance of future therapies.
Introduction
Acute myeloid leukemia (AML) is a malignant disease 
with an age-adjusted incidence of 3.7 per 100,000 men 
and women per year in the United States [1]. The disease 
affects both children and adults. Although about 80% 
of adult patients achieve complete remission after inten-
sive chemotherapy, only 30% to 40% of patients survive 
5 years after diagnosis [2]. Many patients experience a 
relapse, which is caused by the presence of minimal resid-
ual disease (MRD) and in most cases is incurable. There 
are several hypotheses as to why patients develop MRD 
after successful initial response to chemotherapy. The pri-
mary reason for treatment failure in AML is cellular drug 
resistance from both drug efflux and apoptosis-related 
mechanisms, including upstream aberrant signal trans-
duction. Pharmacologic resistance also may play a role.
Resistance mediated by drug efflux occurs in AML 
via high expression of the multidrug resistance (MDR1)
gene (P-glycoprotein [Pgp]) and drug resistance–related 
proteins MRP1 and LRP and has been shown to predict 
poor prognosis [3]. Moreover, patients with a multidrug-
resistant profile at diagnosis have higher MRD frequencies 
after chemotherapy than patients with a more sensitive phe-
notype with regard to Pgp [4]. Apoptosis resistance is also 
important for the development of MRD: high Bcl-2 and/or 
low Bax expression at diagnosis have been shown to predict 
poor survival [5]. Moreover, such an apoptosis-resistant 
profile is correlated with higher levels of MRD after chemo-
therapy [6•]. Recently the bone marrow microenvironment 
has attracted a lot of attention as a key player in modulating 
drug resistance in AML. It has been shown that adhesion 
through integrin engagement triggers chemotherapy resis-
tance of AML blasts [7]. Moreover, blockade of the Wnt 
pathway, an important signal transduction pathway in stem 
cells, by Wnt antagonists supports drug resistance of AML 
[8]. It is likely that these mechanisms also contribute to the 
presence of MRD after chemotherapy. 
Pharmacologic resistance may play a role when a large 
tumor load is present, as has been shown for daunorubicin, 
but the clearance rate of the drug and the cytotoxic activity 
of the major metabolites also may be important [9,10]. 
Finally, the mechanisms mentioned above probably 
contribute to the survival of the leukemic stem cells 
(LSCs), the supposed cells of origin [11–13]. Hypo-
thetically, LSC regrowth leads to the presence of MRD 
and subsequently to relapse [14••].
MRD Detection Methods
In patients with acute leukemia, detection and quantifica-
tion of malignant cells after chemotherapy in remission 
bone marrow (BM) provides powerful prognostic infor-
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mation for the identification of patient risk categories. 
This knowledge is expected to facilitate the early detec-
tion of impending relapse, may result in risk-adapted 
therapies, and may offer a short-term endpoint to assess 
the effectiveness of new, targeted therapies. 
If the leukemic cell at diagnosis carries an antigenic 
or molecular marker that distinguishes it from its normal 
counterpart, this marker can be used after chemotherapy 
to detect residual malignant cells in BM. This allows the 
application of two sensitive methods to identify MRD 
[15] in both acute lymphoblastic leukemia (ALL) and 
AML: multiparameter flow cytometry (MFC) and poly-
merase chain reaction (PCR)–based techniques. Each 
method has its advantages and disadvantages for the 
detection of MRD. 
The clinical importance of MRD detection and 
quantification in adult [16] and childhood [17,18] ALL is 
already established and has been incorporated in pediatric 
ALL trials. Although a number of studies have reported 
on the clinical value of MRD detection in AML in chil-
dren [19,20] and adults [21,22,23•,24•], the information 
provided is still somewhat limited, compared with what 
is known for ALL. We will discuss primarily flow cytom-
etry and also PCR-based strategies for the investigation 
of MRD in patients with AML. A schematic overview 
of new approaches for the detection of MRD is shown 
in Figure 1. Finally, we will discuss a new area in MRD, 
AML stem cells in remission.
Multiparameter flow cytometry
Immunophenotypical analysis of residual leukemic cells 
using MFC is an attractive approach for MRD detection: 
it is sensitive (cell frequency of 10–3 to 10–5), fast, quan-
titative, relatively cheap, and, importantly, applicable to 
more than 90% of patients with AML, many more than 
PCR-based MRD detection [21,22,23•,24•,25]. In con-
trast, both immunophenotypical and PCR-based MRD 
targets are present in the vast majority of patients with 
ALL. Applying quadruple marker combinations, MFC 
uses the presence of aberrant expression of markers, 
usually referred to as leukemia-associated immunophe-
notypes (LAIPs or LAPs) [25]. LAPs are present on all 
leukemic cells or on a subset of them, but they are absent 
or very infrequent on normal BM cells. These LAPs 
result from cross-lineage antigen expression, antigen 
overexpression, antigen underexpression, asynchronous 
antigen expression, and abnormal light scatter pattern 
[25]. Several studies have shown that MRD detection 
based on MFC analysis provides strong prognostic infor-
mation in AML after both induction and consolidation 
therapy [19–22,23•,24•].
Unfortunately, in line with the immunophenotypical 
heterogeneity of AML cells at diagnosis, the LAPs are 
usually not expressed on the whole blast cell population 
[23•]. (In ALL, on the other hand, the cell population is 
immunophenotypically homogenous [17].) The heteroge-
neity of AML cells affects the sensitivity of the approach, 
introducing patient-dependent sensitivity. Other limita-
tions to the applicability of MFC in MRD studies include 
the occurrence of major or minor phenotypic shifts at 
relapse, potentially resulting in false negativity [23•,26]; 
background staining of the normal bone marrow, which 
is LAP-dependent and strongly affects the specificity 
[27]; and the absence of LAPs in some patients.
Polychromatic flow cytometry
MFC techniques are being optimized by technologic 






























Figure 1. Overview of new approaches for 
the detection of minimal residual disease 
(MRD), showing established relationships 
(solid lines) and relationships under investiga-
tion (dashed lines). Molecular or phenotypic 
abnormalities at diagnosis are used to detect 
MRD in bone marrow after chemotherapy. 
The amount of MRD has an impact on 
survival of patients. New approaches include 
the use of six-color polychromic ﬂow cytom-
etry instead of four-color multiparameter 
ﬂow cytometry, the use of peripheral blood 
instead of bone marrow for MRD assess-
ments, and the clinical decisions that can be 
made after MRD assessment, including risk 
stratiﬁcation and/or salvage therapy, in cases 
of increasing MRD frequency.
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of measuring more fluorescence parameters, and new 
software tools capable of analyzing, managing and reduc-
ing the large and complex data sets. Thus, polychromatic 
flow cytometry (PFC) for the detection of different 
fluorochromes (using more than four colors) offers new 
possibilities for MRD detection [28].
One of the key issues in MRD monitoring is specific-
ity. Although four-color flow cytometry is commonly used 
to perform MFC-based MRD detection, monitoring of 
MRD in patients with AML with a LAP that has relatively 
high expression on normal BM counterpart cells would 
benefit from a more specific approach. The inclusion of 
additional markers might better exclude normal BM cells, 
resulting in higher specificity. Using such an approach, it 
has been shown that five-color PFC improves the specific-
ity and reproducibility of MRD monitoring in AML [29]. 
The other advantages of PFC would be to combine differ-
ent four-color LAPs in one newly established composite 
LAP, thereby reducing the amount of BM necessary, the 
number of tubes, costs, and time.
Polymerase chain reaction
An increasing number of studies have shown the clini-
cal importance of PCR-based MRD detection in AML 
[30–32]. Real-time quantitative reverse transcriptase 
PCR (qRT-PCR) is the most sensitive molecular MRD 
detection method used in recent years in AML [31,32]. 
It permits absolute quantification of target DNA or 
mRNA, in contrast to end-point quantification of the 
more classic PCR method. The qRT-PCR technique 
is based on genetic aberrations such as mutations 
and fusion genes, which occur in subgroups of AML. 
Recent and future advances in identifying new AML-
associated genetic aberrations eventually may provide 
such molecular targets for the majority of patients. At 
diagnosis, quantitative PCR (qPCR) enables the assess-
ment of the transcriptional ratio and the kinetics of the 
reduction of the leukemic clone; it offers the possibility 
of early detection of a recurring clone. Although the 
qRT-PCR method may be complex and time-consum-
ing, it is highly sensitive and has been applied for the 
quantification of fusion transcript levels before, during, 
and after therapy.
Molecular targets for PCR-based MRD monitoring
The most common rearrangements producing fusion 
genes in AML are t(8;21), t(15;17), and inv(16)/
t(16;16), which occur in a minority (9% to 19%) of all 
patients with AML and have a favorable prognosis [33]. 
The corresponding fusion transcripts AML1-ETO, 
PML-RARA, and CBFB-MYH11 can be detected by 
qRT-PCR at diagnosis and follow-up to identify MRD 
[34]. Other potential targets for PCR-based MRD detec-
tion in AML are mutations in FLT3, MLL, and NPM1,
and overexpression of WT1, EVI1, and PRAME. The 
usefulness of these targets for MRD detection is pres-
ently under investigation either by single institutions or 
larger networks.
FLT3 mutations
The presence of internal tandem duplications within the 
FLT3 gene (FLT3-ITD) characterizes an unfavorable 
subset of the cytogenetically defined intermediate-risk 
group. These mutations can be detected in about 20% 
to 30% of patients with AML [35]. Previous studies 
showed that not all analyzed patients maintained the 
same FLT3 status at relapse and therefore the results of 
follow-up analysis should be evaluated with special care; 
some patients relapse with a leukemic clone that lacks 
the mutation [36].
MLL-PTD mutations
The frequency of partial tandem duplications of the MLL
gene (MLL-PTD), which are indicative of an unfavorable 
outcome, is 3% to 4% at diagnosis and up to 10% in AML 
with normal karyotype. It has been shown that MRD 
monitoring is possible using these MLL aberrations [37].
NPM1 mutations
Mutations of the nucleophosmin member 1 (NPM1) gene 
occur predominantly in patients who have AML with 
normal karyotype; it has been reported to occur in 46% 
to 62% of these cases [38]. A recent study suggested that 
qPCR assays for NPM1 mutations is suitable for moni-
toring and quantifying MRD in patients with AML and 
normal karyotypes [39].
WT1 overexpression
The Wilms tumor gene (WT1) encoding a zinc finger 
transcription factor is a tumor suppressor gene that 
functions as a potent transcriptional repressor of sev-
eral growth factors. Overexpression is related to the 
maintenance of the viability of leukemic cells through 
regulation of Bcl-2 expression [40]. WT1 overexpres-
sion can be detected in almost all AML patients, and 
high levels of WT1 after chemotherapy are predictive 
for survival [41,42]. Recently the MRD Working Party 
of the European Leukemia Network (www.leukemia-
net.org) decided to explore the possibilities of WT1 as 
an MRD marker. 
EVI1 overexpression
The EVI1 gene, which is associated with rearrange-
ments of 3q26, is overexpressed in 20% of patients 
with newly diagnosed AML and is associated with poor 
prognosis [43]. To our knowledge, no studies on the 
use of EVI1 overexpression as a marker for MRD have 
been published.
PRAME overexpression
Overexpression of the preferentially expressed antigen 
of melanoma (PRAME) gene has been found in 62% of 
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children with AML and is correlated with a favorable out-
come [44]. A good correlation between PRAME mRNA 
expression after chemotherapy and disease status has 
been found [45].
Comparison of MFC and qRT-PCR
It is important to compare the value for patient prognosis 
of quantifications of MRD based on qRT-PCR and MFC. 
Several reports using patients with ALL showed generally 
concordant results [46,47], but few data are available on 
this issue in AML. A recent study has shown high correla-
tions between PCR-based and MFC-based MRD detection 
and recommends the combined use of both techniques 
[48]. Although qRT-PCR is more sensitive than MFC in 
quantifying MRD in patients with translocations, it is 
unknown how many patients can be subjected to PCR-
based strategies using all the new targets that have been 
identified, as these have not been studied together. Further 
prospective studies are needed to define the best approach 
for MRD monitoring in AML patients.
Blood versus bone marrow for MRD measurements
In all MRD studies in patients with AML, measurements 
are performed on BM samples. It would of course be 
convenient for both patient and doctor to use peripheral 
blood (PB) instead, but only one relevant study has been 
performed in AML [49]. This study described the clear-
ance of blasts from the PB at days 1 to 8 after the start of 
chemotherapy, which correlated with MRD frequency in 
the BM at day +14. Clearly more studies are necessary. 
Regarding molecular MRD assessments, Goulden et 
al. [50] reported results of the Medical Research Council 
AML 15 trial in patients with acute promyelocytic leuke-
mia. It was found that BM is more reliable than PB for the 
detection of PML-RARB. For t(8,21), only one study in 
pediatric AML showed that PB was equal to BM [51]. For 
ALL, the use of PB instead of BM has been extensively 
studied. It was concluded that BM samples cannot easily 
be replaced by PB sampling for MRD analysis in child-
hood precursor-B-ALL, in line with the BM origin of this 
disease [52,53]. In T-ALL, which is of thymic origin, BM 
sampling might be replaced by PB, probably because the 
dissemination of T-ALL cells to BM and PB is comparable 
[53]. Because AML is also of BM origin, it may not be 
possible for PB to simply replace BM. At present, there is 
not enough evidence that PB sampling can replace BM, 
except possibly for AML M3.
Multicenter MRD Analysis and 
Prospective Studies
The ultimate goal of MRD studies is implementation in 
clinical practice for both risk stratification and guidance 
of clinical intervention. To this end, consensus in MRD 
analysis is necessary and guidelines should be published 
enabling uniformity of all procedures, thereby allowing 
MRD analysis in multiple centers. In The Netherlands 
and Belgium, a working group, the Dutch/Belgium Task 
Force for MRD detection in AML, composed of several 
academic centers in cooperation with the European Soci-
ety for Clinical Cell Analysis (ESCCA), has been initiated 
to prepare MRD guidelines. Recently, consensus has been 
reached on the analysis of AML samples in the diagnos-
tic phase and end terms have been determined (Feller, 
Unpublished data). The next target is to achieve consen-
sus regarding analysis in the MRD phase, based on the 
end terms defined for the diagnostic phase. This effort 
ultimately should result in consensus guidelines for MRD 
analysis that can be applied in different centers.
To definitely prove the value of MRD measurements, 
prospective studies are needed to answer two important 
questions: 1) Can MRD assessment identify high-risk 
patients within both the standard-risk and good-risk 
groups, who require additional or more intensive therapy 
regimens? 2) Can MRD assessment identify those at very 
low risk of relapse, who might be candidates for reduction 
of treatment? The Dutch hemato-oncology association, 
the HOVON, has recently started the HOVON-42A 
protocol for the treatment of patients with AML who 
are aged under 60 years. In this multicenter, prospec-
tive, randomized study, patients are treated with two 
induction courses and one consolidation course. One of 
the major side studies is a prospective study on the value 
of MRD assessments using MFC. BM samples are col-
lected for both MFC and PCR, allowing a retrospective 
comparison between molecular and immunophenotypi-
cal MRD. The HOVON study 81 also will include BM 
sampling for MRD studies in patients aged 60 or older. 
St. Jude Children’s Research Hospital in Tennessee, USA, 
has already performed a prospective single-center study 
of flow cytometry in AML with a relatively small number 
of children [20]. 
Multicenter trials are needed for stratification of AML 
patients based on their MRD frequency, to see whether 
patients can benefit from reduced or intensified treatment 
regimens. For acute promyelocytic leukemia, studies have 
been published on salvage therapy. Preliminary evidence 
from the GIMEMA group suggests a survival benefit for 
pre-emptive therapy (at a stage of molecularly resistant dis-
ease) when compared with treatment at the point of relapse 
[54]. This shows that pre-emptive therapy is potentially 
beneficial. For comparison, many studies in pediatric ALL 
patients in both the United States and Europe have already 
included MRD frequency assessments as a risk-stratifica-
tion step with consequences for therapy. Regarding adult 
patients, in the German Multicenter ALL (GMALL) trial, 
salvage treatment is intended to be started at the time of 
recurrence of quantifiable MRD.
MRD as a short-term endpoint in clinical studies
In recent years, many new targets have been identified 
that need testing in clinical practice. However, the study 
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designs that are generally used require the accrual of many 
patients and a long follow-up. Short-term endpoints would 
be of great importance to evaluate new randomized phase 
II trials with new treatment modalities. Because MRD 
reflects the sum of all parameters contributing to quality 
of response to therapy, it might serve as an early endpoint 
to assess effectiveness of new therapeutic modalities. The 
correlation of multidrug resistance [4], apoptosis [6•], and 
FLT3-ITD [55] at diagnosis with MRD frequencies indi-
cates that such an approach is very promising.
Stem Cells and MRD
CD34+CD38–
AML is generally regarded as a stem cell disease. In 
CD34-positive AML, the stem cell has been recognized as 
CD38-negative [11]. It is also generally thought that LSCs 
preferentially survive chemotherapy and grow out to cause 
the presence of MRD, which leads to relapse of the disease 
in some cases. If so, stem cell characteristics at diagnosis 
should show a correlation with MRD cell frequency after 
chemotherapy, which indeed was found for the frequency 
of the CD34+CD38– population at diagnosis [14••]. 
Because MRD frequency shows a strong correlation 
with survival [21,22,23•,24•], we hypothesized that the 
CD34+CD38– cell frequency itself at diagnosis should be 
directly correlated with the survival of patients, and this 
indeed was the case (Fig. 2) [14••].
Similar to the characterization of the leukemic 
blasts using LAP expression, the identification of immu-
nophenotypical characteristics specific for the malignant 
CD34+CD38– cells at diagnosis would offer opportunities 
to study the stem cell compartment after chemotherapy. This 
information in turn would enable not only identification of 
patients at risk for relapse, but also the characterization of 
these cells, which could then help to identify new targets for 
therapy. One of the possible markers, CD123, is expressed 
on most AML blasts and on the leukemic CD34+CD38– 
subpopulation at diagnosis; it is reported not to be present 
on normal CD34+CD38– cells [56]. Also CD33, a com-
mon myeloid antigen, is present on both the majority of the 
blasts and on the CD34+CD38– cells. Recently, however, 
Taussig et al. [57•] reported that both CD33 and CD123 
were present not only on malignant CD34+CD38– cells 
but also on the normal BM CD34+CD38– counterpart. 
We obtained similar results, especially for BM regenerating 
after chemotherapy (van Rhenen, Unpublished data). Thus, 
neither CD123 nor CD33 may be suitable to specifically 
detect malignant CD34+CD38– cells in the BM of patients 
with AML during or after chemotherapy. 
Therefore the search for markers that are specifically 
expressed on AML stem cells but not on normal stem cells 
is ongoing. Recently we have found that C-type lectin-
like molecule-1 (CLL-1) may represent such an antigen. 
CLL-1 expression on AML blasts is comparable to CD33 
expression [58•] and, moreover, is present on malignant 
CD34+CD38– cells in the majority of patients with AML 
who are positive for CLL-1 at diagnosis [59]. In contrast to 
CD123 and CD33, normal CD34+CD38– cells lack CLL-
1 expression under all conditions of disease (van Rhenen, 
Unpublished data). In addition (and unexpectedly), many 
lineage-associated antigens, which make up most of the 
LAPs already discussed, were found to be prominently 
present on the AML CD34+CD38– compartment but not 
on the steady state and regenerating normal bone mar-
row CD34+CD38– counterpart [60]. The lineage markers 
thus can be used for the detection of residual malignant 
CD34+CD38– cells in BM during or after therapy. 
In conclusion, specific detection of malignant 
CD34+CD38– cells after chemotherapy is possible using 
CLL-1 and lineage marker expression, but it probably is 
not possible using the presumed LSC marker CD123 or 
CD33. CD33 is the target of gemtuzumab ozogamicin 
(Mylotarg®, Wyeth Pharmaceuticals, Philadelphia, PA), 
presently used in the clinic. The presumed expression of 
CD33 on normal stem cells likely offers part of the expla-
nation for the toxicities seen with this therapy.
Side population
The CD34+CD38– compartment does not provide the 
stem cell compartment for all patients with AML. At 
diagnosis, 5% of patients with AML who have a CD34+ 
phenotype lack a detectable CD34+CD38– compartment 
(< 0.01%) and about 20% are CD34 negative and thereby, 
by definition, CD34+CD38– negative [14••]. An alterna-
tive stem cell compartment for these patients is offered 
by the so-called side population (SP). A decade ago, 
Goodell et al. [61] reported the presence of an extremely 
small but distinct population of cells in normal BM of 
mice, capable of efficient Hoechst 33342 dye efflux. This 











Figure 2. This ﬁgure shows the interrelationships between stem cells 
(CD34+CD38–), frequency of minimal residual disease (MRD), and 
patient survival. Solid lines represent established relationships and 
dashed lines represent possible relationships that are under investi-
gation. At diagnosis, stem cell frequency can be determined, which 
correlates with both MRD frequency after chemotherapy [14••] and 
survival [14••]. MRD frequency itself is related to survival [23•] and 
also to the MRD stem cell frequency, which in turn may have an 
impact on survival of patients. It remains to be established whether 
these results are also true for the leukemic stem cell side population.
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cells (HSCs). This HSC population was identified too in 
human BM and shown to be largely CD34 negative with 
a high repopulation potential and successful engraftment 
in mice [62]. SP cells are also present in BM obtained 
from patients with AML, and these were capable of ini-
tiating leukemia after transplantation into NOD/SCID 
mice, suggesting that these cells might be candidate LSCs 
[63]. Moreover, AML-specific cytogenetic abnormalities 
were present in SP cells obtained both at diagnosis and 
after chemotherapy in remission BM. These findings 
suggested that SP cells in normal BM may be a target for 
leukemic transformation.
The immunophenotypical characteristics of SP cells 
have not yet been analyzed in great detail. Both CD34 and 
CD38 showed a large range of expression with large inter-
individual differences. The precise relationship between 
SP cells and the antigenic marker–defined CD34+CD38– 
subset is unknown. Of interest, the SP cell frequency is 
much lower than the CD34+CD38– cell frequency (in our 
hands, median 0.02% vs 0.44% of white blood cells). The 
immunophenotype of AML SP cells, in addition to being 
reported as CD34+CD38– or CD34–CD38–, may also be 
CD34+CD38+ [64].
SP cells may be partly or completely positive for the 
lineage markers CLL-1, CD123, or both, strongly sug-
gesting that most SP cells represent the malignant clone, 
which in a few cases could be confirmed by FISH analysis 
[65]. Furthermore, SP cells from normal BM and control 
regenerating BM were completely negative for CLL-1 and 
the lineage markers, but not for CD123. Similar to the 
CD34+CD38–, using these discriminative markers, SP cell 
frequency after chemotherapy paralleled normal (“whole 
blast”) MRD and clinical outcome [66].
Thus, SP cells indicating AML can be discriminated 
from normal SP cells based on the expression of CLL-1 
and lineage markers, and these markers can be used for 
the detection of MRD SP cells in BM after therapy. Future 
studies using PFC, which enables the use of Hoechst 
staining together with multiple marker combinations, will 
elucidate the relationship between the SP stem cell com-
partment and the CD34+CD38– stem cell compartment. 
Clinical implications of MRD stem cell detection in AML
Recent insights into the nature of normal and malignant 
stem cells have led to the identification of quiescent and 
drug-resistant LSCs as likely candidates responsible for 
relapse [11,14••]. To predict impending relapses prior to 
clinical manifestations and to manage patient-adapted 
postremission therapies, it may be of great importance 
to detect MRD stem cells after chemotherapy using 
CD34+CD38– or SP AML phenotypes, besides detect-
ing MRD using the whole blast compartment. Evidence 
for this role comes from the observation that AML stem 
cell parameters offer prognostic information additional to 
MRD frequency assessment [60,66].
Apart from such clinically applicable prognostic 
information, the flow cytometric approaches detect 
viable malignant CD34+CD38– and/or SP populations, 
thereby allowing further characterization of these cells 
with the aim of developing new therapies directed at 
stem cells or applying present therapies in a more patient-
tailored way. Moreover, as interaction of LSCs with the 
BM microenvironment, the stem cell niche, is important 
for their survival [11,14••], future studies should also 
focus on the molecular mechanisms involved in the 
interactions between the stem cell niche and the LSCs to 
determine the therapeutic windows for new anticancer 
therapies directed at LSCs in a clinical setting [11,14••].
Conclusions
MRD detection in AML has shown prognostic signifi-
cance. Immunophenotypical and PCR-based methods 
should be compared, including all new targets that are 
available for PCR-based strategies. PFC might enable 
more specific analysis than MFC. The preferential study 
material is still BM. After prognostic MRD studies, it 
may become possible to apply MRD monitoring to clini-
cal decision making. The introduction of stem cells in 
MRD studies may further improve the clinical signifi-
cance of these studies and may reveal the most relevant 
target-cell population for the design of new therapies.
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